CA2800722C - Systemes et procedes pour analyse multi-variable de donnees d'evenements defavorables - Google Patents
Systemes et procedes pour analyse multi-variable de donnees d'evenements defavorables Download PDFInfo
- Publication number
- CA2800722C CA2800722C CA2800722A CA2800722A CA2800722C CA 2800722 C CA2800722 C CA 2800722C CA 2800722 A CA2800722 A CA 2800722A CA 2800722 A CA2800722 A CA 2800722A CA 2800722 C CA2800722 C CA 2800722C
- Authority
- CA
- Canada
- Prior art keywords
- medication
- adverse event
- analyzer
- patient
- identification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 305
- 238000000491 multivariate analysis Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 1199
- 229940079593 drug Drugs 0.000 claims abstract description 1196
- 230000000694 effects Effects 0.000 claims abstract description 424
- 230000008685 targeting Effects 0.000 claims abstract description 69
- 238000002648 combination therapy Methods 0.000 claims abstract description 34
- 238000002483 medication Methods 0.000 claims description 222
- 108090000623 proteins and genes Proteins 0.000 claims description 216
- 102000004169 proteins and genes Human genes 0.000 claims description 210
- 229940124301 concurrent medication Drugs 0.000 claims description 75
- 230000004913 activation Effects 0.000 claims description 31
- 230000003213 activating effect Effects 0.000 claims description 28
- 239000005557 antagonist Substances 0.000 claims description 26
- 239000000556 agonist Substances 0.000 claims description 24
- 230000000415 inactivating effect Effects 0.000 claims description 21
- 230000002411 adverse Effects 0.000 abstract description 95
- 239000003596 drug target Substances 0.000 abstract description 69
- 230000002068 genetic effect Effects 0.000 abstract description 27
- 230000004001 molecular interaction Effects 0.000 abstract description 24
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 206010060933 Adverse event Diseases 0.000 description 436
- 230000037361 pathway Effects 0.000 description 90
- 238000003860 storage Methods 0.000 description 51
- 230000035772 mutation Effects 0.000 description 42
- 238000004458 analytical method Methods 0.000 description 37
- 102000004190 Enzymes Human genes 0.000 description 36
- 108090000790 Enzymes Proteins 0.000 description 36
- 238000010586 diagram Methods 0.000 description 27
- 210000000056 organ Anatomy 0.000 description 25
- 108010042653 IgA receptor Proteins 0.000 description 21
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 230000003993 interaction Effects 0.000 description 20
- 238000012545 processing Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 238000004891 communication Methods 0.000 description 17
- 230000006854 communication Effects 0.000 description 17
- 108010078791 Carrier Proteins Proteins 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 11
- 230000009456 molecular mechanism Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 9
- 208000010201 Exanthema Diseases 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 9
- 201000005884 exanthem Diseases 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 206010037844 rash Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 206010067484 Adverse reaction Diseases 0.000 description 7
- 230000006838 adverse reaction Effects 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010013710 Drug interaction Diseases 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 206010061623 Adverse drug reaction Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000003190 augmentative effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000009434 installation Methods 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000013479 data entry Methods 0.000 description 4
- 229960001433 erlotinib Drugs 0.000 description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
- 229960002584 gefitinib Drugs 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 229960004891 lapatinib Drugs 0.000 description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 230000036642 wellbeing Effects 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001875 compounds Chemical group 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000008406 drug-drug interaction Effects 0.000 description 3
- 108091007999 druggable proteins Proteins 0.000 description 3
- 102000038037 druggable proteins Human genes 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- -1 pathway Proteins 0.000 description 3
- 238000012913 prioritisation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000007473 univariate analysis Methods 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 201000009916 Postpartum depression Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000012268 genome sequencing Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000000092 prognostic biomarker Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 1
- 241000501754 Astronotus ocellatus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 102100025287 Cytochrome b Human genes 0.000 description 1
- 108010075028 Cytochromes b Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102100034581 Dihydroorotase Human genes 0.000 description 1
- 108091000126 Dihydroorotase Proteins 0.000 description 1
- 206010016948 Food interaction Diseases 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 208000036647 Medication errors Diseases 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 101100521334 Mus musculus Prom1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000012896 Statistical algorithm Methods 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 150000001607 bioavailable molecules Chemical class 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medical Treatment And Welfare Office Work (AREA)
Abstract
La présente divulgation concerne des systèmes et procédés pour analyse multi-variable de données dévénements défavorables. Selon un premier aspect, des informations génomiques propres au patient sont utilisées pour optimiser la thérapie du patient ou atténuer les risques de ladite thérapie. Selon dautres aspects de linvention, des cibles de médicaments inconnues sont identifiées par lintermédiaire de données dévénements défavorables. Selon dautres aspects encore, un médicament est identifié pour exclure de lutilisation pour une indication ou dun essai clinique dun autre médicament. Selon un autre aspect, un profil deffets secondaires prédit est généré pour un médicament ciblant une nouvelle cible. Selon un autre aspect encore, des polythérapies sont identifiées par lintermédiaire de données dévénements défavorables. Selon un autre aspect, des interactions moléculaires entre une pluralité dentités moléculaires sont affichées dans un format intuitif. Selon un autre aspect encore, les entités moléculaires responsables des différences des événements défavorables entre des indications semblables sont identifiées. Selon un autre aspect encore, les variants génétiques associés aux événements défavorables dans un essai clinique sont identités.
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584164P | 2012-01-06 | 2012-01-06 | |
| US61/584,164 | 2012-01-06 | ||
| US201261605626P | 2012-03-01 | 2012-03-01 | |
| US61/605,626 | 2012-03-01 | ||
| US13/446,820 US20130179187A1 (en) | 2012-01-06 | 2012-04-13 | Systems and methods for de-risking patient treatment |
| US13/446,871 US9218457B2 (en) | 2012-01-06 | 2012-04-13 | Systems and methods for identifying unknown drug targets via adverse event data |
| US13/446,912 | 2012-04-13 | ||
| US13/446,871 | 2012-04-13 | ||
| US13/446,820 | 2012-04-13 | ||
| US13/446,917 US9779214B2 (en) | 2012-01-06 | 2012-04-13 | Systems and methods for personalized de-risking based on patient genome data |
| US13/446,912 US9235686B2 (en) | 2012-01-06 | 2012-04-13 | Systems and methods for using adverse event data to predict potential side effects |
| US13/446,917 | 2012-04-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2800722A1 CA2800722A1 (fr) | 2013-07-06 |
| CA2800722C true CA2800722C (fr) | 2020-12-29 |
Family
ID=48742074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2800722A Active CA2800722C (fr) | 2012-01-06 | 2013-01-04 | Systemes et procedes pour analyse multi-variable de donnees d'evenements defavorables |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2800722C (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10803144B2 (en) | 2014-05-06 | 2020-10-13 | International Business Machines Corporation | Predicting drug-drug interactions based on clinical side effects |
| CN107145735B (zh) * | 2017-05-04 | 2019-08-06 | 中国药科大学 | 一种评估药物发生不良反应倾向的方法 |
| CN112786104B (zh) * | 2021-02-03 | 2024-03-22 | 东北大学 | 基于机器学习的药物疗效影响因子挖掘方法 |
-
2013
- 2013-01-04 CA CA2800722A patent/CA2800722C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2800722A1 (fr) | 2013-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9619624B2 (en) | Systems and methods for identifying unknown drug targets via adverse event data | |
| US11309090B2 (en) | Method and process for predicting and analyzing patient cohort response, progression, and survival | |
| US20130268290A1 (en) | Systems and methods for disease knowledge modeling | |
| Gill et al. | Emerging role of bioinformatics tools and software in evolution of clinical research | |
| Huang et al. | Systematic prediction of drug combinations based on clinical side-effects | |
| Pittman et al. | AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks | |
| Tsai et al. | iScreen: world’s first cloud-computing web server for virtual screening and de novo drug design based on TCM database@ Taiwan | |
| Reimand et al. | GraphWeb: mining heterogeneous biological networks for gene modules with functional significance | |
| Xia et al. | A cross-study analysis of drug response prediction in cancer cell lines | |
| EP2600269A2 (fr) | Modélisation de réseau et d'échantillonnage de microréseau pour prédiction de toxicité de médicaments | |
| Pathak et al. | Using linked data for mining drug-drug interactions in electronic health records | |
| Wang et al. | SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery | |
| Chowbina et al. | HPD: an online integrated human pathway database enabling systems biology studies | |
| Blucher et al. | Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz | |
| CA2800722C (fr) | Systemes et procedes pour analyse multi-variable de donnees d'evenements defavorables | |
| Soldatos et al. | Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports | |
| Benstead-Hume et al. | ‘Big data’approaches for novel anti-cancer drug discovery | |
| EP2801047B1 (fr) | Systèmes et procédés d'analyse multivariée de données d'événements indésirables | |
| EP3815095A1 (fr) | Dispositif informatique à interface d'utilisateur améliorée destiné à interpréter et visualiser des données | |
| Seo et al. | GRACOMICS: software for graphical comparison of multiple results with omics data | |
| Tsongalis | Advances in Molecular Pathology | |
| JP7462685B2 (ja) | 縦方向データを解釈して視覚化するための改善されたユーザインタフェースを有するシステムおよび方法 | |
| Kosman et al. | A Systematic Literature Review Approach To Clinical Trial Informatics Systems: Case of caBIG and its Clinical Trial Management System | |
| Tercan et al. | SL-Cloud: A Cloud-based resource to support synthetic lethal interaction discovery | |
| Bal et al. | Java for bioinformatics and biomedical applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171220 |